The overexpression of caveolin-1 and caveolin-2 correlates with a poor prognosis and tumor progression in esophageal squamous cell carcinoma

Oncology Reports

Volumn 18, Issue 3, 2007, Pages 601-609

  Ando, Takuya ^a   Ishiguro, Hideyuki ^a   Kimura, Masahiro ^a   Mitsui, Akira ^a   Mori, Yoichiro ^a   Sugito, Nobuyoshi ^a   Tomoda, Keisuke ^a   Mori, Ryota ^a   Harada, Koshiro ^a   Katada, Takeyasu ^a   Ogawa, Ryo ^a   Fujii, Yoshitaka ^a   Kuwabara, Yoshiyuki ^a  

^a NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

Caveolin 1; Caveolin 2; Esophageal squamous cell carcinoma

Indexed keywords

CAV1 PROTEIN, HUMAN; CAVEOLIN 1; CAVEOLIN 2; MESSENGER RNA; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER INVASION; CANCER STAGING; DISEASE COURSE; ESOPHAGUS TUMOR; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; SURVIVAL; TUMOR CELL LINE;

AGED; CARCINOMA, SQUAMOUS CELL; CAVEOLIN 1; CAVEOLIN 2; CELL LINE, TUMOR; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL ANALYSIS;

EID: 38449093572     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.18.3.601     Document Type: Article

References (32)

1. Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, Mitsui A, Nishiwaki T, Moriyama S, Kudo J and Fujii Y: Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer 95: 92-95, 2001. (Pubitemid 32187079)
2. Konishi S, Ishiguro H, Shibata Y, Kudo J, Terashita Y, Sugiura H, Koyama H, Kimura M, Sato A, Shinoda N, Kuwabara Y and Fujii Y: Decreased expression of DFF45/ICAD is correlated with a poor prognosis in patients with esophageal carcinoma. Cancer 95: 2473-2478, 2002. (Pubitemid 35424031)
3. Shibata Y, Haruki N, Kuwabara Y, Nishiwaki T, Kato J, Shinoda N, Sato A, Kimura M, Koyama H, Toyama T, Ishiguro H, Kudo J, Terashita Y, Konishi S and Fujii Y: Expression of PTTG (pituitary tumor transforming gene) in esophageal cancer. Jpn J Clin Oncol 32: 233-237, 2002. (Pubitemid 43102805)
4. Shibata Y, Haruki N, Kuwabara Y, Ishiguro H, Shinoda N, Sato A, Kimura M, Koyama H, Toyama T, Nishiwaki T, Kudo J, Terashita Y, Konishi S, Sugiura H and Fujii Y: Chfr expression is downregulated by CpG island hypermethylation in esophageal cancer. Carcinogenesis 23: 1695-1699, 2002.
5. Terashita Y, Sasaki H, Haruki N, Nishiwaki T, Ishiguro H, Shibata Y, Kudo J, Konishi S, Kato J, Koyama H, Kimura M, Sato A, Shinoda N, Kuwabara Y and Fujii Y: Decreased peroxisome proliferator-activated receptor gamma gene expression is correlated with poor prognosis in patients with esophageal cancer. Jpn J Clin Oncol 32: 238-243, 2002. (Pubitemid 43102806)
6. Terashita Y, Ishiguro H, Haruki N, Sugiura H, Tanaka T, Kimura M, Shinoda N, Kuwabara Y and Fujii Y: Excision repair cross complementing 3 expression is involved in patient prognosis and tumor progression in esophageal cancer. Oncol Rep 12: 827-831, 2004.
7. Takashima N, Ishiguro H, Kuwabara Y, Kimura M, Haruki N, Ando T, Kurehara H, Sugito N, Mori R and Fujii Y: Expression and prognostic roles of PABPC1 in esophageal cancer: correlation with tumor progression and postoperative survival. Oncol Rep 15: 667-671, 2006.
8. Ando T, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Kurehara H, Sugito N, Tomoda K, Mori R, Takashima N, Ogawa R and Fujii Y: Expression of ACP6 is an independent prognostic factor for poor survival in patients with esophageal squamous cell carcinoma. Oncol Rep 15: 1551-1555, 2006.
9. Marx J: Caveolae: a once-elusive structure gets some respect. Science 294: 1862-1865, 2001.
10. Galbiati F, Razani B and Lisanti MP: Emerging themes in lipid rafts and caveolae. Cell 106: 403-411, 2001. (Pubitemid 32786984)
11. Scherer PE, Lewis RY, Volonte D, Engelman JA, Galbiati F, Couet J, Kohtz DS, van Donselaar E, Peters P and Lisanti MP: Cell-type and tissue-specific expression of caveolin-2. Caveolins 1 and 2 co-localize and form a stable hetero-oligomeric complex in vivo . J Biol Chem 272: 29337-29346, 1997. (Pubitemid 27498228)
12. Smart EJ, Graf GA, McNiven MA, Sessa WC, Engelman JA, Scherer PE, Okamoto T and Lisanti MP: Caveolins, liquid-ordered domains, and signal transduction. Mol Cell Biol 19: 7289-7304, 1999. (Pubitemid 29493393)
13. Williams TM, Hassan GS, Li J, Cohen AW, Medina F, Frank PG, Pestell RG, Di Vizio D, Loda M and Lisanti MP: Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice. J Biol Chem 280: 25134-25145, 2005. (Pubitemid 40934606)
14. Suzuoki M, Miyamoto M, Kato K, Hiraoka K, Oshikiri T, Nakakubo Y, Fukunaga A, Shichinohe T, Shinohara T, Itoh T, Kondo S and Katoh H: Impact of caveolin-1 expression on prognosis of pancreatic ductal adenocarcinoma. Br J Cancer 87: 1140-1144, 2002. (Pubitemid 35418110)
15. Fine SW, Lisanti MP, Galbiati F and Li M: Elevated expression of caveolin-1 in adenocarcinoma of the colon. Am J Clin Pathol 115: 719-724, 2001. (Pubitemid 33051539)
16. Van den Eynden GG, van Laere SJ, van der Auwera I, Merajver SD, van Marck EA, van Dam P, Vermeulen PB, Dirix LY and van Golen KL: Overexpression of caveolin-1 and -2 in cell lines and in human samples of inflammatory breast cancer. Breast Cancer Res Treat 95: 219-228, 2006.
17. Kato K, Hida Y, Miyamoto M, Hashida H, Shinohara T, Itoh T, Okushiba S, Kondo S and Katoh H: Overexpression of caveolin-1 in esophageal squamous cell carcinoma correlates with lymph node metastasis and pathologic stage. Cancer 94: 929-933, 2002. (Pubitemid 34150846)
18. Wikman H, Seppanen JK, Sarhadi VK, Kettunen E, Salmenkivi K, Kuosma E, Vainio-Siukola K, Nagy B, Karjalainen A, Sioris T, Salo J, Hollmen J, Knuutila S and Anttila S: Caveolins as tumour markers in lung cancer detected by combined use of cDNA and tissue microarrays. J Pathol 203: 584-593, 2004. (Pubitemid 38529039)
19. Bender FC, Reymond MA, Bron C and Quest AF: Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res 60: 5870-5878, 2000.
20. Davidson B, Nesland JM, Goldberg I, Kopolovic J, Gotlieb WH, Bryne M, Ben-Baruch G, Berner A and Reich R: Caveolin-1 expression in advanced-stage ovarian carcinoma - a clinicopathologic study. Gynecol Oncol 81: 166-171, 2001. (Pubitemid 32424155)
21. Sagara Y, Mimori K, Yoshinaga K, Tanaka F, Nishida K, Ohno S, Inoue H and Mori M: Clinical significance of Caveolin-1, Caveolin-2 and HER2/neu mRNA expression in human breast cancer. Br J Cancer 91: 959-965, 2004. (Pubitemid 39273791)
22. Sloan EK, Stanley KL and Anderson RL: Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene 23: 7893-7897, 2004. (Pubitemid 39457039)
23. Aldred MA, Ginn-Pease ME, Morrison CD, Popkie AP, Gimm O, Hoang-Vu C, Krause U, Dralle H, Jhiang SM, Plass C and Eng C: Caveolin-1 and caveolin-2,together with three bone morphogenetic protein-related genes, may encode novel tumor suppressors down-regulated in sporadic follicular thyroid carcinogenesis. Cancer Res 63: 2864-2871, 2003.
24. Hu YC, Lam KY, Law S, Wong J and Srivastava G: Profiling of differentially expressed cancer-related genes in esophageal squamous cell carcinoma (ESCC) using human cancer cDNA arrays: overexpression of oncogene MET correlates with tumor differentiation in ESCC. Clin Cancer Res 7: 3519-3525, 2001. (Pubitemid 33069989)
25. Couet J, Sargiacomo M and Lisanti MP: Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J Biol Chem 272: 30429-30438, 1997. (Pubitemid 27512253)
26. Timme TL, Goltsov A, Tahir S, Li L, Wang J, Ren C, Johnston RN and Thompson TC: Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis. Oncogene 19: 3256-3265, 2000. (Pubitemid 30487412)
27. Razani B, Zhang XL, Bitzer M, von Gersdorff G, Bottinger EP and Lisanti MP: Caveolin-1 regulates transforming growth factor (TGF)-beta/SMAD signaling through an interaction with the TGF-beta type I receptor. J Biol Chem 276: 6727-6738, 2001.
28. Galbiati F, Volonte D, Brown AM, Weinstein DE, Ben-Ze'ev A, Pestell RG and Lisanti MP: Caveolin-1 expression inhibits Wnt/beta-catenin/Lef-1 signaling by recruiting beta-catenin to caveolae membrane domains. J Biol Chem 275: 23368-23377, 2000. (Pubitemid 30646240)
29. Li L, Ren CH, Tahir SA, Ren C and Thompson TC: Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol 23: 9389-9404, 2003. (Pubitemid 37499824)
30. Gingras D, Gauthier F, Lamy S, Desrosiers RR and Beliveau R: Localization of RhoA GTPase to endothelial caveolae-enriched membrane domains. Biochem Biophys Res Commun 247: 888-893, 1998. (Pubitemid 28418486)
31. Lee H, Volonte D, Galbiati F, Iyengar P, Lublin DM, Bregman DB, Wilson MT, Campos-Gonzalez R, Bouzahzah B, Pestell RG, Scherer PE and Lisanti MP: Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-Src/Cav-1/Grb7 signaling cassette. Mol Endocrinol 14: 1750-1775, 2000.
32. Razandi M, Oh P, Pedram A, Schnitzer J and Levin ER: ERs associate with and regulate the production of caveolin: implications for signaling and cellular actions. Mol Endocrinol 16: 100-115, 2002. (Pubitemid 34044501)